Shire PLC (LON:SHP) has been reiterated to Overweight in a statement by JP Morgan Cazenove earlier today.
- Updated: October 18, 2016
JP Morgan Cazenove has reiterated Shire PLC (LON:SHP) to Overweight in a statement released on 10/19/2016.
On 10/17/2016, Bryan Garnier released a statement on Shire PLC (LON:SHP) upped the target price from 2,240.00GBX to 6,900.00GBX that suggested an upside of 0.35%.
Having a price of 5,148.50GBX, Shire PLC (LON:SHP) traded 1.32% higher on the day. With the last close up 11.25% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. SHP has recorded a 50-day average of 5,022.47GBX and a two hundred day average of 4,625.73GBX. Trade Volume was up over the average, with 1,945,451 shares of SHP changing hands over the typical 1,885,230
Recent Performance Chart
Shire PLC has PE ratio of 32.08 with a one year low of 2,707.19GBX and a one year high of 5,377.00GBX and has a market capitalization of 0 GBX.
A total of 18 analysts have released a report on Shire PLC. Six analysts rating the company a strong buy, sixteen analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of 73.73GBX.
General Company Details For Shire PLC (LON:SHP)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.